Cancer Archives

News and Trends 12 Dec 2022

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

brain cancer glioblastoma divide and conquer

News and Trends 12 Dec 2022

Enterome completes patient enrollment for recurrent glioblastoma study

Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead OncoMimics candidate, EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer. Enterome is a French clinical stage company developing first-in-class immunomodulatory drugs […]

December 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Step Pharma announces promising pre-clinical cancer data

Step Pharma has announced encouraging pre-clinical data on its first-in-class, highly selective, orally bioavailable CTPS1 inhibitor, STP938. The data were presented at the 64th American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The data presented by Step Pharma collaborators demonstrates the potential of STP938, a highly selective CTPS1 inhibitor, as a therapeutic […]

December 12, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Siddhartha Mukherjee, assistant professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division […]

December 9, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from […]

December 9, 2022

News and Trends 8 Dec 2022

PDCline Pharma presents first immunological results from trial with PDClung01

PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […]

December 8, 2022 - 3 minutesmins - By Liza Laws

More News! 8 Dec 2022

Enhertu’s positive results demonstrate improvement in overall survival

Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […]

December 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Dec 2022

New method uses metabolism to detect cancers

When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for. An international study led by researchers from Chalmers University of Technology, Sweden, shows that a new, previously untested method can easily find multiple types of newly formed cancers at the same […]

December 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Laevoroc Oncology pushes for relapsed leukemia cure

Laevoroc Oncology, a privately-owned, Swiss oncology development company, has announced the publication of key preclinical data carried out at the University of California, Los Angeles (UCLA), which provides mechanistic insights into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09. The research shows that PNP is a novel metabolic immune […]

December 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

DNA repair mechanism study could boost cancer treatment

A better understanding of the mechanisms involved in DNA repair may pave the way for developing inhibitors to improve the effectiveness of radiation therapy. Nucleotide excision repair (NER) is a critical DNA repair pathway that plays a key role in maintaining transcription and genome integrity by removing bulky DNA lesions. The key steps in the […]

December 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Ibex and Source announce agreement to aid pathologists with diagnostic accuracy

An agreement has been announced between Ibex Medical Analytics and Source LDPath, part of Source BioScience. It will expand the deployment of artificial intelligence (AI) to Source’s entire pathology network. Ibex works with AI-powered cancer diagnostics and the expansion builds on its previous work with LDPath. Source, which provides integrated laboratory services and products, acquired […]

December 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Dec 2022

Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, has signed a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalized cancer immunotherapy. The agreement focuses on the provision of clinical material for use in Odimma’s oncological neoantigen program. Through the deal, Odimma will gain access to […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

Enterome completes patient enrollment for recurrent glioblastoma study

Step Pharma announces promising pre-clinical cancer data

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

PDCline Pharma presents first immunological results from trial with PDClung01

Enhertu’s positive results demonstrate improvement in overall survival

New method uses metabolism to detect cancers

Laevoroc Oncology pushes for relapsed leukemia cure

DNA repair mechanism study could boost cancer treatment

Ibex and Source announce agreement to aid pathologists with diagnostic accuracy

Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!